Multiple specialists are involved in the treatment of psoriatic arthritis. We conducted an on-line survey to clarify the current status of clinical practices of psoriatic arthritis as well as that of collaboration among doctors. We obtained responses from 141 delegates (31.0%) in the Japanese Dermatological Association and 123 councilors (12.2%) in the Japan College of Rheumatology. Although the target of the survey was rather limited, both dermatologists and rheumatologists referred to or collaborated with other specialists when needed, and they were generally satisfied with the results of such multidisciplinary managements. However, they sometimes found difficulties in collaborating with other specialists because of lack of mutual communication, and many doctors agreed upon the necessity of educational activities for doctors and patients and of consolidation of the whole medical care system. The medications used for the treatment of psoriatic arthritis differed considerably according to the specialty of a doctor. For a better management of patients, it is important to further facilitate collaboration among doctors and take advantage of their expertise.
We developed a questionnaire to determine the findings of cutaneous arteritis (cutaneous polyarteritis nodosa) among dermatological experienced vasculitis specialists as certified by the Committee for guidelines for the management of vasculitis and vascular disorders of the Japanese Dermatological Association. Retrospective data obtained from all patients at 12 dermatological facilities between January of 2012 and December of 2016 were evaluated. Fever, cerebral hemorrhage, and cerebral infarction were found in more than 10% of cases during our follow-up period. Arthralgia and/or arthritis (37%), myalgia and/or myositis (21%), and peripheral neuropathy (33%) were the most prominent findings in the study. Systemic steroid treatment was administered in only half of these cases. We believe that such patients, who are originally diagnosed as having CA, can progress from CA to systemic polyarteritis nodosa if they do not receive appropriate treatment such as systemic steroid therapy.